A randomized, multicenter trial assessing the effects of rapastinel compared to ketamine, alprazolam, and placebo on simulated driving performance
- PMID: 34423904
- PMCID: PMC8742651
- DOI: 10.1111/cts.13145
A randomized, multicenter trial assessing the effects of rapastinel compared to ketamine, alprazolam, and placebo on simulated driving performance
Abstract
N-methyl-D-aspartate ionotropic glutamatergic receptor (NMDAR) modulators, including rapastinel and ketamine, elicit rapid and sustained antidepressant responses in patients with treatment-resistant major depressive disorder. This phase I, randomized, multicenter, placebo-controlled, five-period, crossover, single-dose study evaluated simulated driving performance of healthy participants (N = 107) after single doses of rapastinel slow intravenous (i.v.) bolus 900 and 1800 mg, alprazolam oral 0.75 mg (positive control), ketamine i.v. infusion 0.5 mg/kg (clinical comparator), and placebo ~ 45 min before driving. The primary end point was SD of lateral position (SDLP) during the 60-min 100-km simulated driving scenario. Additional measures of driving performance, sleepiness, and cognition were also evaluated. To assess effects over time, mean SDLP was calculated for each 10-min interval of driving. Sensitivity of the assays was confirmed with alprazolam (all placebo comparisons p < 0.02). Rapastinel 900 and 1800 mg did not significantly affect simulated driving performance compared to placebo (both p > 0.5). Both rapastinel doses resulted in significantly less impaired driving compared to alprazolam or ketamine (all p < 0.002); ketamine significantly impaired driving compared to placebo (p = 0.0001). Results for the additional measures were similar to the primary end point. No new safety signals were observed for any study interventions. This first study of rapastinel effects on simulated driving found that rapastinel 900 and 1800 mg did not impair driving performance, but ketamine 0.5 mg/kg resulted in significantly impaired driving performance. Ketamine's effects on driving were maintained for at least 105 min, indicating that clinicians should be vigilant to prevent or postpone driving in patients after ketamine treatment.
Trial registration: ClinicalTrials.gov NCT03814733.
© 2021 AbbVie. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.
Conflict of interest statement
R.B. is a full‐time employee at AbbVie, Inc. (previously Allergan plc). S.S., J.R., C.S., and A.P. are former full‐time employees at AbbVie, Inc. (previously Allergan plc). T.H. (Chief Executive Officer, Owner) and G.K. (President, Chief Scientific Officer, Owner) of Cognitive Research Corporation and G.K. (Author, Owner) of CogScreen.
Similar articles
-
Glutamatergic receptor and neuroplasticity in depression: Implications for ketamine and rapastinel as the rapid-acting antidepressants.Biochem Biophys Res Commun. 2022 Feb 26;594:46-56. doi: 10.1016/j.bbrc.2022.01.024. Epub 2022 Jan 17. Biochem Biophys Res Commun. 2022. PMID: 35074585 Review.
-
The effects of intranasal esketamine (84 mg) and oral mirtazapine (30 mg) on on-road driving performance: a double-blind, placebo-controlled study.Psychopharmacology (Berl). 2017 Nov;234(21):3175-3183. doi: 10.1007/s00213-017-4706-6. Epub 2017 Jul 28. Psychopharmacology (Berl). 2017. PMID: 28755104 Free PMC article. Clinical Trial.
-
Positive N-Methyl-D-Aspartate Receptor Modulation by Rapastinel Promotes Rapid and Sustained Antidepressant-Like Effects.Int J Neuropsychopharmacol. 2019 Mar 1;22(3):247-259. doi: 10.1093/ijnp/pyy101. Int J Neuropsychopharmacol. 2019. PMID: 30544218 Free PMC article.
-
GLYX-13 (rapastinel) ameliorates subchronic phencyclidine- and ketamine-induced declarative memory deficits in mice.Behav Brain Res. 2016 Feb 15;299:105-10. doi: 10.1016/j.bbr.2015.10.060. Epub 2015 Nov 26. Behav Brain Res. 2016. PMID: 26632337 Free PMC article.
-
Rapastinel, a novel glutamatergic agent with ketamine-like antidepressant actions: Convergent mechanisms.Pharmacol Biochem Behav. 2020 Jan;188:172827. doi: 10.1016/j.pbb.2019.172827. Epub 2019 Nov 13. Pharmacol Biochem Behav. 2020. PMID: 31733218 Review.
Cited by
-
Combination administration of alprazolam and N-Ethylmaleimide synergistically enhances sleep behaviors in mice with no potential CNS side effects.PeerJ. 2024 May 7;12:e17342. doi: 10.7717/peerj.17342. eCollection 2024. PeerJ. 2024. PMID: 38737745 Free PMC article.
-
Utilizing Technology to Enhance the Ecological Validity of Cognitive and Functional Assessments in Schizophrenia: An Overview of the State-of-the-Art.Schizophr Bull Open. 2024 Nov 28;5(1):sgae025. doi: 10.1093/schizbullopen/sgae025. eCollection 2024 Jan. Schizophr Bull Open. 2024. PMID: 39676763 Free PMC article.
-
Driving performance and ocular activity following acute administration of 10 mg methylphenidate: A randomised, double-blind, placebo-controlled study.J Psychopharmacol. 2024 Nov;38(11):998-1006. doi: 10.1177/02698811241286715. Epub 2024 Oct 11. J Psychopharmacol. 2024. PMID: 39394668 Free PMC article. Clinical Trial.
-
Ketamine Evolving Clinical Roles and Potential Effects with Cognitive, Motor and Driving Ability.Neurol Int. 2023 Mar 3;15(1):352-361. doi: 10.3390/neurolint15010023. Neurol Int. 2023. PMID: 36976666 Free PMC article. Review.
-
A scoping review of motor vehicle operator performance assessments for benzodiazepine receptor agonists.Explor Res Clin Soc Pharm. 2024 Nov 9;16:100538. doi: 10.1016/j.rcsop.2024.100538. eCollection 2024 Dec. Explor Res Clin Soc Pharm. 2024. PMID: 39634377 Free PMC article.
References
-
- Friedrich MJ. Depression is the leading cause of disability around the world. JAMA. 2017;317:1517. - PubMed
-
- Greenberg PE, Fournier AA, Sisitsky T, Pike CT, Kessler RC. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J Clin Psychiatry. 2015;76:155‐162. - PubMed
-
- Warden D, Rush AJ, Trivedi MH, Fava M, Wisniewski SR. The STAR*D Project results: a comprehensive review of findings. Cur Psychiatr Rep. 2007;9:449‐459. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical